Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 1/20 | 0.57 |
| ▸ | AURKA | O14965 | 14/20 | 0.52 |
| ▸ | AURKB | Q96GD4 | 9/20 | 0.52 |
| ▸ | GSK3B | P49841 | 6/20 | 0.52 |
| ▸ | SRC | P12931 | 4/20 | 0.52 |
| ▸ | GSK3A | P49840 | 2/20 | 0.52 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | GBA1 | P04062 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12653571 | 0.86 | AURKA (0.70) | ITKAURKAAURKBGSK3BSRC | |
| SCHEMBL802286 | 0.79 | ITK (0.69) | ITKAURKAAURKBGSK3BSRC | |
| SCHEMBL3804199 | 0.77 | ITK (0.66) | ITKAURKAAURKBGSK3BSRC | |
| SCHEMBL786648 | 0.76 | RET (0.61) | ITKAURKAAURKBGSK3BSRC | |
| SCHEMBL802002 | 0.75 | ITK (0.63) | ITKAURKAAURKBGSK3BSRC | |
| SCHEMBL3961786 | 0.74 | AURKA (0.51) | AURKAAURKBGSK3BSRCGSK3A | |
| SCHEMBL802275 | 0.73 | ITK (1.00) | ITKAURKAAURKBGSK3BSRC | |
| SCHEMBL802004 | 0.72 | ITK (0.50) | ITKAURKAAURKBGSK3BSRC | |
| SCHEMBL805517 | 0.72 | MEN1 (0.59) | ITKAURKAAURKBGSK3BSRC | |
| SCHEMBL11790523 | 0.72 | MAPT (0.51) | MEN1KMT2ACYP1A2ADRB2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633210-B2 | Triazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-21 | — | — | US | disclosed |
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | GSK3B, GSK3A, CDK19 | ITK 1124/4885AURKA 8/4885AURKB 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.